FDA Notice Reclassifying Baxter's Autopheresis-C Includes Special Controls
This article was originally published in The Gray Sheet
Executive Summary
FDA will require equipment failure rates to be reported as part of 510(k) applications for Baxter's Autopheresis-C automated plasmapheresis system, following the device's reclassification from Class III to Class II.
You may also be interested in...
BAXTER AUTOPHERESIS-C DOWNCLASSIFICATION RECOMMENDED BY BLOOD PRODUCTS PANEL; PETITION SUPPORTED BY LOW INCIDENCE OF ADVERSE EVENT DEVICE REPORTS
Baxter's Autopheresis-C blood separation system's clinical safety record supports downclassification from Class III to Class II, FDA's Blood Products Advisory Committee concluded at a Sept. 27 meeting in Bethesda, Maryland.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.